Philip Ma is Chief Executive Officer, President, and Founder of PrognomiQ, a leader in developing and commercializing transformative healthcare products for the early detection and treatment of cancer and other complex diseases. PrognomiQ is an independent company that spun-out of Seer, a leader in transforming the field of proteomics, and in which Philip was formerly Chief Business Officer, President and Founder. Earlier, Philip was Vice-President of Digital Health Technology and Data Sciences at Biogen, where he applied transformative digital technologies and advanced data analyses across the company. Before Biogen, he was Senior Partner at McKinsey & Company, serving leading pharmaceuticals, biotechnology, and medical products companies. In community affairs, Philip served on the board of directors for the United Way of Silicon Valley for 10 years; he is also a current board member of Committee of 100.
Earlier in life, he conducted research at the Massachusetts Institute of Technology, earning his Ph.D. in biology. He is a Rhodes Scholar and holder of an M.Phil. degree in economics from Oxford University; and has an A.B. degree in biochemistry from Harvard University.